CCS
SCLN

Crosspoint Capital Strategies’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Crosspoint Capital Strategies’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-687
Closed -$9K – 133
2016
Q2 		$9K Buy
+687
New +$9K 0.01% 72

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crosspoint Capital Strategies's SCLN Position: Q3 2016 in Review

Crosspoint Capital Strategies sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2016, closing a stake of 687 shares — an estimated $9K sold.

Crosspoint Capital Strategies first reported a position in SCLN in Q2 2016 and held it in 1 quarter. The position peaked at $9K in Q2 2016. 151 funds tracked by Wall St. Rank hold SCLN as of Q3 2016.

  • Crosspoint Capital Strategies reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 687 Sciclone Pharmaceuticals Inc shares in Q3 2016, an estimated $9K.
  • Crosspoint Capital Strategies first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Sciclone Pharmaceuticals Inc position peaked at $9K in Q2 2016.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2016, filed 9 Nov 2016.